Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
We aimed to explore efficacy and safety of Boiogito treatment, in combination with conventional medical therapy for chronic heart failure patients with cardiorenal syndrome (CRS). Boiogito was increased up to 7.5 g/day, and patients were evaluated at 3.5 and 9.4 months. Boiogito treatment significantly increased mean estimated glomerular filtration rate and decreased mean levels of blood urea nitrogen, serum creatinine and brain natriuretic peptide. Efficacy and safety of Boiogito treatment for both renal function and heart failure status were demonstrated in patients with CRS.
|